8-K filing — Arbutus Biopharma Corp (ABUS)
Filed: 2026-11-12 AccNo: 0001171843-26-007378 Size: 7 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified "Dutch
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-12 AccNo: 0001171843-26-007378 Size: 7 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Arbutus Biopharma reported its third quarter 2026 financial results, highlighting a net income of $59.1 million and the lifting of a U.S. FDA clinical hold on its oral PD-L1 inhibitor, AB-101.
Arbutus Biopharma Corporation has been notified by the U.S. Food and Drug Administration that the clinical hold on its Investigational New Drug application for AB-101 has been removed.